Durability and tolerability of dapagliflozin over 52weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 11, 2015, Pages 1075-1084

  Matthaei, S ^a   Bowering, K ^b   Rohwedder, K ^c   Sugg, J ^c   Parikh, S ^c   Johnsson, E ^d  

^a Diabetes Zentrum Quakenbruck   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Dapagliflozin; Metformin; SGLT2 inhibitor; Sulphonylureas

Indexed keywords

C PEPTIDE; DAPAGLIFLOZIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CHOLESTEROL; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BLADDER CANCER; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATURIA; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN SENSITIVITY; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT REDUCTION; AGED; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL;

AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; URINARY TRACT INFECTIONS;

EID: 84944597723     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12543     Document Type: Article

References (30)

1. Bosi E. Metformin-the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 2009; 11(Suppl. 2): 3-8.
2. Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy 2004; 24: 606-620.
3. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996; 39: 503-514.
4. Hermann LS, Lindberg G, Lindblad U, Melander A. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes. Diabetes Obes Metab 2002; 4: 296-304.
5. Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care 2015; 38(Suppl.): S4.
6. Garber AJ, Abrahamson MJ, Barzilay JI etal. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract 2013; 19: 536-557.
7. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
8. Petznick AM. Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus. J Am Osteopath Assoc 2013; 113: S6-16.
9. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36(Suppl. 2): S127-138.
10. Jabbour SA. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med 2014; 126: 111-117.
11. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012; 5: 313-327.
12. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
13. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-456.
14. Nauck MA, Del Prato S, Duran-Garcia S etal. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014; 16: 1111-1120.
15. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
16. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2013; 16: 124-136.
17. Farxiga Prescribing information. AstraZeneca/Bristol Myers Squibb. Available at: http://www.azpicentral.com/farxiga/pi_farxiga.pdf#page=1. Last accessed 20 January 2014.
18. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015; 38: 365-372.
19. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014; 37: 740-750.
20. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014; 5: 267-283.
21. Guthrie RM. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med 2013; 125: 21-32.
22. Hach T, Gerich J, Salsali A etal. Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trials. Diabetologia 2013; 56(Suppl. 1): S377.
23. Rosenstock J, Aggarwal N, Polidori D etal. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
24. Haring HU, Merker L, Seewaldt-Becker E etal. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
25. Nyirjesy P, Sobel JD, Fung A etal. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-1119.
26. Komoroski B, Vachharajani N, Boulton D etal. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
27. Nauck MA, Del Prato S, Meier JJ etal. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
28. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-741.
29. Lewin A, Lipetz R, Wu J, Schwartz S. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. Clin Ther 2007; 29: 844-855.
30. Wilding JP, Charpentier G, Hollander P etal. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.